[cta_card cta_head=”The drug access process” cta_subhead=”testet” cta_style=”cta__lg” cta_align=”cta__right” link=”url:%23|title:Learn%20about%20the%20drug%20access%20process” image_url=”337″]In Canada, new drugs undergo a multi-step review and approval process—known as the drug access process—before they are available for use.[/cta_card]

Status of ALS treatments in Canada

Disclaimer: ALS Canada does not endorse or recommend any specific treatments.

Please consult your ALS clinician for information and advice on specific treatments.

ALBRIOZA (AMX0035)

NDS submitted to Health Canada
New Drug Submission

The drug is now commercially available in Canada. Canadian Agency for Drugs and Technologies in Health (CADTH) and L’Institut national d’excellence en santé et en services sociaux (INESSS) released its reimbursement recommendations.

View drug details

RADICAVA (edaravone)

RADICAVA (edaravone) is an intravenous medication for the treatment of ALS developed by the drug company, Mitsubishi Tanabe Pharma Corporation (MTPC).

View drug details

RADICAVA (edaravone)

RADICAVA (edaravone) is an intravenous medication for the treatment of ALS developed by the drug company, Mitsubishi Tanabe Pharma Corporation (MTPC).

View drug details

RADICAVA (edaravone)

RADICAVA (edaravone) is an intravenous medication for the treatment of ALS developed by the drug company, Mitsubishi Tanabe Pharma Corporation (MTPC).

View drug details

RADICAVA (edaravone)

Available, with conditions
Approved

RADICAVA (edaravone) is an intravenous medication for the treatment of ALS developed by the drug company, Mitsubishi Tanabe Pharma Corporation (MTPC).

View drug details

RADICAVA (edaravone)

Discontinued
Discontinued

RADICAVA (edaravone) is an intravenous medication for the treatment of ALS developed by the drug company, Mitsubishi Tanabe Pharma Corporation (MTPC).

View drug details

Want to learn more about ALS treating drugs?

Learn more about ALS Treatments
View clinical trials in canada